• Tolerability
For access to clinical studies and other Differin® Gel, 0.3% physician resources, click here. Register.

Favorable Tolerability You Want

In a phase 3, 12-week, randomized, vehicle-controlled study comparing adapalene gel, 0.3%, adapalene gel, 0.1%, and gel vehicle in the treatment of acne vulgaris (N=653), the incidence of scaling, dryness, and stinging/burning was noted early in the study, but signs and symptoms of skin irritation were transient in duration, peaking during the first weeks and decreasing over time. Signs and symptoms of skin irritation were mostly mild or moderate in severity. Few patients experienced severe erythema (0.4% vs 0.8% for adapalene gel, 0.3% and adapalene gel, 0.1% respectively), scaling (1.2% vs 1.6%), dryness (0.8% vs 2.7%), or stinging/burning (3.6% vs 3.9%), with comparable incidence in the adapalene gel, 0.3% and adapalene gel, 0.1% treatment groups.3

important safety info

Important Safety Information

Differin® Gel, 0.3% and Differin® Lotion 0.1% are both indicated for the topical treatment of acne vulgaris in patients 12 years and older. Adverse events reported with use of Differin® products include skin dryness, erythema, scaling, stinging and burning. Most adverse events reported were mild to moderate in severity, occurred early in treatment and decreased thereafter. With use of Differin® Gel 0.3%, adverse events may also include general skin discomfort, pruritus and sunburn. Excessive exposure to sunlight and sunlamps should be avoided during treatment with all Differin® products, and use of sunscreen products and protective clothing is recommended. Concomitant use of drying or irritating topical products (like products containing resorcinol, salicylic acid or sulfur) should be used with caution. Instruct patients to avoid the eyes, lips and mucous membranes when applying Differin® products, and not to apply to areas that have been depilated with wax products. Differin® products have not been tested in pregnant or nursing women, or with the elderly. Both Differin® Gel, 0.3% and Differin® Lotion 0.1% are Pregnancy Category C. Please see full Prescribing Information for Differin Gel, 0.3% and please see full Prescribing Information for Differin Lotion, 0.1%.
©2012 Galderma Laboratories, L.P. United States, All Rights Reserved. All trademarks are the property of their respective owners. This site intended for U.S. audiences only. Information in this website is not intended as medical advice. Talk to your doctor about medical concerns.
This site is intended for US healthcare professionals only.
Are you a healthcare professional?

Important Safety Information

Differin® Gel, 0.3% and Differin® Lotion 0.1% are both indicated for the topical treatment of acne vulgaris in patients 12 years and older. Adverse events reported with use of Differin® products include skin dryness, erythema, scaling, stinging and burning. Most adverse events reported were mild to moderate in severity, occurred early in treatment and decreased thereafter. With use of Differin® Gel 0.3%, adverse events may also include general skin discomfort, pruritus and sunburn. Excessive exposure to sunlight and sunlamps should be avoided during treatment with all Differin® products, and use of sunscreen products and protective clothing is recommended. Concomitant use of drying or irritating topical products (like products containing resorcinol, salicylic acid or sulfur) should be used with caution. Instruct patients to avoid the eyes, lips and mucous membranes when applying Differin® products, and not to apply to areas that have been depilated with wax products. Differin® products have not been tested in pregnant or nursing women, or with the elderly. Both Differin® Gel, 0.3% and Differin® Lotion 0.1% are Pregnancy Category C. Please see full Prescribing Information for Differin Gel, 0.3% and please see full Prescribing Information for Differin Lotion, 0.1%.